AdoRx Therapeutics
Edinburgh
About AdoRx Therapeutics
AdoRx Therapeutics is pursuing the discovery of new therapeutics for cancer based on modulation of the adenosine pathway. High levels of adenosine in the tumour microenvironment enable cancer to evade the immune system. AdoRx’s lead programs are focused on the design of “fit for purpose” adenosine receptor antagonists that will overcome the effects of high adenosine levels. AdoRx Therapeutics is a UK-based drug discovery company and backed by investment from Epidarex Capital and Sixth Element Capital. The AdoRx leadership team have discovered in excess of 25 clinical candidates and have greater than 60 years combined experience of drug discovery in biotech and pharma.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $10.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Jun 2018)
- Website: adorx.com
- Phone: +01312 433 704
Industries & Categories
Biotechnology, Health Care, Therapeutics
Canonical: https://fsome.com/organization/adorx-therapeutics-99290 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.